Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “overweight” rating reaffirmed by research analysts at Morgan Stanley in a report issued on Friday, Benzinga reports. They presently have a $60.00 target price on the biopharmaceutical company’s stock. Morgan Stanley’s price target indicates a potential upside of 77.04% from the stock’s current price. A number […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has received a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month target price […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) EVP Fady Ibraham Malik sold 2,500 shares of the firm’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $35.37, for a total value of $88,425.00. Following the transaction, the executive vice president now owns 160,664 shares in the company, […]
Peregrine Capital Management LLC grew its position in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 24.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 199,416 shares of the biopharmaceutical company’s stock after purchasing an additional 39,273 shares during the period. Peregrine Capital […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) CEO Robert I. Blum sold 12,500 shares of the stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $35.28, for a total value of $441,000.00. Following the completion of the transaction, the chief executive officer now directly owns 441,417 shares […]